Loading
journalsJournal
Nature Reviews Drug Discovery
Nature Reviews Drug Discovery is Springer Nature's monthly review journal on how drugs are discovered and developed. Its News and Analysis pieces are the usual source for the pipeline, clinical success-rate and attrition statistics quoted about oncology development, so investors and policy analysts read it as much as scientists.
Also called: Nat Rev Drug Discov
Overview
Nature Reviews Drug Discovery (Nat Rev Drug Discov) is a monthly review journal from Springer Nature, founded in 2002, covering how drugs are discovered and developed. It publishes commissioned reviews on drug targets and modalities, plus News and Analysis pieces tracking pipelines, approvals, clinical success rates and R&D costs. It is a major source for the 'probability of success' and pipeline-attrition statistics that frame oncology development, so its readers include drug developers, investors and policy analysts as well as scientists. Within OnCo it is linked from the Howard Kaufman biography, and a reader would use it for pipeline and success-rate data and for reviews of new therapeutic modalities.
observational2022177 citations
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Two bottleneck pages and eleven idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
review20222,725 citations
PROTAC targeted protein degraders: the past is prologue
One pathway page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
review2020946 citations
'Off-the-shelf' allogeneic CAR T cells: development and challenges
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
review2017469 citations
DNA-encoded chemistry: enabling the deeper sampling of chemical space
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
review2017704 citations
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
One of the most cited reviews Europe PMC returns for BCL-2 in Chronic lymphocytic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Howard L. Kaufman
Surgical Oncologist, Massachusetts General Hospital; Chief Medical Officer, Ankyra Therapeutics
Oncolytic virus therapyMelanomaIntratumoural immunotherapy
Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy.
Robert S. Langer
David H. Koch (1962) Institute Professor
Drug deliveryBiomaterialsNanomedicine
Biomedical engineer whose Koch Institute lab pioneered controlled drug delivery and nanomedicine, including approaches to cancer therapy.
observationalNature Reviews Drug Discovery 2022177 citations
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Two bottleneck pages and eleven idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
reviewNature Reviews Drug Discovery 20222,725 citations
PROTAC targeted protein degraders: the past is prologue
One pathway page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
reviewNature Reviews Drug Discovery 2020946 citations
'Off-the-shelf' allogeneic CAR T cells: development and challenges
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
reviewNature Reviews Drug Discovery 2017469 citations
DNA-encoded chemistry: enabling the deeper sampling of chemical space
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
reviewNature Reviews Drug Discovery 2017704 citations
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
One of the most cited reviews Europe PMC returns for BCL-2 in Chronic lymphocytic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
people
key papers
'Off-the-shelf' allogeneic CAR T cells: development and challengesChallenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscapeDNA-encoded chemistry: enabling the deeper sampling of chemical spaceFrom basic apoptosis discoveries to advanced selective BCL-2 family inhibitorsPROTAC targeted protein degraders: the past is prologue